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ON THE ANALYSIS OF PERSONALIZED MEDICATION
RESPONSE AND CLASSIFICATION OF CASE VS
CONTROL PATIENTS IN MOBILE HEALTH STUDIES:
THE MPOWER CASE STUDY
By Elias Chaibub Neto, Thanneer M Perumal, Abhishek
Pratap, Brian M Bot, Lara Mangravite, Larsson Omberg
In this work we provide a couple of contributions to the analysis
of longitudinal data collected by smartphones in mobile health appli-
cations. First, we propose a novel statistical approach to disentangle
personalized treatment and “time-of-the-day” effects in observational
studies. Under the assumption of no unmeasured confounders, we
show how to use conditional independence relations in the data in
order to determine if a difference in performance between activity
tasks performed before and after the participant has taken medica-
tion, are potentially due to an effect of the medication or to a “time-
of-the-day” effect (or still to both). Second, we show that smartphone
data collected from a given study participant can represent a “digi-
tal fingerprint” of the participant, and that classifiers of case/control
labels, constructed using longitudinal data, can show artificially im-
proved performance when data from each participant is included in
both training and test sets. We illustrate our contributions using data
collected during the first 6 months of the mPower study.
1. Introduction. Smartphones offer a unique opportunity to develop
large scale studies of human health[1, 2]. Features extracted from data col-
lected by accelerometers, microphones, and touch screen sensors can pro-
vide objective measurements of human health and disease. Mobile health
technologies may provide an unprecedented opportunity to improve overall
management of global disease burden and health care costs. First, they may
support the application of specialized medical care to remote populations
that were previously under-served due to lack of local availability. Second,
they may enable personalization of treatments in a manner that can safely
and effectively meet individual medical needs while minimizing unintended
negative outcomes, thereby reducing the overall burden of health care. In
particular, smartphones can be used to determine if a patient is likely re-
sponding to its medication[3, 4].
In the mPower (mobile Parkinsons observatory for worldwide evidence-
based research) study, a participant is asked to perform distinct activity
tasks, including speeded tapping, voice, gait, and balance tests[10]. Raw
sensor data collected from each task is processed into activity specific fea-
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2tures. Because the activity tasks are performed by the patient on a daily
basis, before and after medication, over a long period of time, the processed
data corresponds to time series of feature measurements, annotated accord-
ing to whether the measurement was taken before or after the participant
has taken medication. For each activity task, we extract several features.
Here, we describe a statistical approach to disentangle putative treatment
effects from putative “time-of-the-day” effects in observational studies, and
apply it to data collected in the first 6 months of the mPower study. In
this application, we are mostly interested in detecting the effect of levadopa
on the participant’s performance in an activity task (as measured by the
difference in the participant’s performance when medicated in comparison
to when the participant is unmedicated). But, because it is the participant
who decides when he/she will perform the activity task, it is possible that
any observed difference in performance might be due to circadian rhythms
or daily routine activities (as well as, to long term confounders) instead of
due to the medication.
We use the recorded time-of-the-day that the activity was performed as
a surrogate variable for the short term cyclic potential influences and model
treatment and time-of-the-day effects under the assumption of no unmea-
sured confounders. (In a previous contribution we propose the use of in-
strumental variables in randomized experiments with imperfect compliance
as an approach to account for unmeasured confounders[4].) The present ap-
proach is based on conditional independence tests implemented via t-tests in
linear regression models, and represents an improvement over another pre-
vious contribution[3]. We discuss how residual autocorrelation can inflate
(or deflate) the t-test p-values, and we propose the use of ARIMA processes
and heterocedasticity and autocorrelation consistent estimators of covari-
ance as remedies to these issues. Finally, we describe how to combine the
results of the feature specific conditional independence tests into a single
union-intersection testing procedure.
Our second contribution, is to describe an interesting phenomenon ob-
served in the mPower data, namely, that the sensor data collected from a
study participant provides a digital fingerprint of the participant. This ob-
servation has important practical consequences for any analyses performed
at a population level. In particular, for the classification of Parkinson’s di-
asease (PD) cases versus healthy controls one needs to be careful when
designing the training/test random split used for building the case/control
classifier, since if data from each participant is included in both the train-
ing and test set, then the classifier performance can be artificially improved
because the digital fingerprint makes it easy to discriminate one participant
3from another. We start by illustrating this issue in detail.
2. On the classification of PD patients and healthy controls us-
ing smartphone sensor data: the digital fingerprint phenomenon.
Several smartphone based studies have focused in Parkinson’s disease[5, 6,
7, 8, 9, 3]. Current tests for the diagnosis of PD are based on subjective
neurological examinations performed in-clinic (although the use of objective
measurements collected by smartphones has been proposed as a potential
alternative approach to the remote characterization of PD[5, 6]).
Here, we investigate the accuracy of the classification of PD participants
versus healthy controls in data collected during the first 6 months of the
mPower study. Because each participant contributes several samples to the
study, we end up with longitudinal data for each extracted feature. We an-
alyzed each activity task separately, using a subset of PD cases and healthy
controls with age distributions spread over similar ranges (see Figure 1).
We found out that smartphone data collected from a given study partic-
ipant can represent a “digital signature”, or a “digital fingerprint”, of the
participant. As a consequence, one needs to be careful when designing the
train/test split of the data used to train a case/control classifier. Explicitly,
if data from each participant is included in both the training and test set,
as illustrated in Figure 2, then the classifier performance can be artificially
improved because it is easy to discriminate one participant from another. In
other words, the classifier is able to learn about individual characteristics of
the participants to a greater extent than about the differences between cases
and controls. To illustrate this point we apply a random forest classifier[11] to
a randomly chosen (and balanced) subset of the approximately age matched
data from Figure 1 in order to classify not only cases versus controls, but
also distinct random groups of participants, generated by block shuffling the
case/control labels as described in Figure 3.
Figure 4a presents the performance of the random forest classifier accord-
ing to the area under the receiver operating characteristic curve (AUC).
For each one of the separate activity tasks, the data was composed of 10
randomly selected PD cases, 10 randomly selected healthy controls, and fea-
tures extracted from 100 randomly selected activity tasks per participant.
The boxplots in Figure 4a represent the results of 100 random splits of
the data into equally sized training and test sets, as described in Figure 2.
Note that for the boxplots in the right (“block shuffled labels”), each one
of the train/test random splits used a distinct version of the block shuffled
labels, whereas the boxplots in the left (“original labels”) used the same
case/control original labels in all 100 train/test random splits. (We used
4mPower study (first 6 months)
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Fig 1. The top left panel shows age distributions for PD cases (blue) and healthy controls
(red) in the first 6 months of the mPower study. Due to the poor overlap of the distri-
butions (note the much younger control population), we focus our analyses on a subset
of participants with age distributions spread over similar ranges (namely, between 61 and
86 years). For the tapping activity our analyses where restricted to 315 cases and 109
controls, while the voice analyses focused on 277 cases and 96 controls, and the walk (and
rest) analyses employed 170 cases and 69 controls. (The distributions are different for the
different tasks because participants perform the distinct tasks with different frequencies.)
the same 100 random train/test splits in the analysis of the original and
block shuffled labels.) The figure clearly shows that the performance of the
case/control classification is comparable to the random group classifications,
showing that a random forest classifier is equally able to discriminate be-
tween any two arbitrarily chosen groups of participants, as between PD
cases and healthy controls. This observation suggests that the classifiers are
mostly learning the individual characteristics of each participant, or, in other
words, the digital fingerprints of the participants. To further corroborate this
point we also employed a random forest to evaluate our ability to classify the
participants in a multi-class classification problem, where the classes corre-
spond to the participant identities. Figure 4b shows that the AUCs of the
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Fig 2. Train/test split where the data contributed by each participant is included in both
the training and test set. The schematic represents a data set composed of 4 PD cases
(participants 1 to 4), and 4 healthy controls (participants 5 to 8). Each participant has
longitudinal data from n activity tasks, and the full feature data matrix is composed of 8n
rows/samples and p columns/features. The vector of case/control labels has 8n elements,
with PD labels shown in dark and healthy control labels shown in light color. The full data
set is randomly split in two equally sized training and test sets, with both sets containing
approximately n/2 samples from each one of the participants.
multi-class classifier were slightly higher than of the binary classification,
even though the multi-class classification is a much harder problem (recall
that because we have 20 participants, the probability of correctly guessing
the identity of a participant is only 0.05, while in the binary classification
problem we can guess the correct class half of the time on average).
Note that while the training/test split described in Figure 2 is perfectly
valid from the machine learning perspective (as the classifier is trained and
evaluated in completely separated data sets), the digital fingerprint phe-
nomenon creates, nonetheless, a serious artifact, and clearly illustrates that
one should avoid including data from each participant in both training and
test sets. Observe, as well, that the digital fingerprint of a participant may
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Fig 3. Generation of random groups of participants by blocked shuffling of the case and
control labels. The schematic shows 10 distinct examples (RG 1 to RG 10) of arbitrarily
chosen groups of participants generated by randomly shuffling the participant’s labels as a
block. For instance, the first random group (RG 1) was generated by randomly shuffling
the original labels (as blocks) so that the labels of participants 1, 2, and 4 changed from
“case” to “control”, the labels of participants 5, 6, and 7 changed from “control” to “case”,
and the labels of participants 3 and 8 remained the same. (Note that for each participant
the labels are changed across all n samples.) For each random group, the data is split into
training and test sets, as described in Figure 2, and a classifier is trained to predict the
random group labels.
arise not only from biological characteristics of a participant, but also from
non-biological artifacts. For instance, it is likely that non-biological artifacts
such as the length of the room where a participant performs the walking
task might influence the extracted features in the walking activity (since
the shorter the room, the larger the number of turns a participant will need
to do during the 30 seconds of duration of the task, and it is not unreasonable
to expect that the acceleration patterns will pick up these differences).
In order to circumvent the digital fingerprint issue, we adopt a train/test
split where the data contributed by each participant is either included in the
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Fig 4. Panel a shows the performance comparison of the case/control (original labels)
versus random groups (block shuffled labels) classification, when data contributed by each
participant is included in both the training and test set. We analyzed the tapping, voice,
walk, and rest activities, separately (employing 41, 116, 19, and 13, tap, walk, rest, and
voice features, respectively). The PD cases and healthy controls were randomly selected
from the larger set of approximately age matched participants described in Figure 1. Panel
b shows the comparison of the classification AUC in the multi-class problem (classifying the
participant identities) versus the binary classification of cases/controls. Results based on
the train/test random split described in Figure 2. For the multi-class AUC computation,
we adopted the one-vs-one approach[12]. In both panels, the grey boxplots represent the
results for completely shuffled labels across all samples (where the same participant can
have samples labeled as cases and controls).
training or in the test set, as described in Figure 5. Figure 6a reports the
performance of the case/control classification using the exact same data as
in Figure 4a, but adopting the train/test random split described in Figure 5.
It clearly shows weaker average classification performances and considerably
larger variability, in comparison to the results in Figure 4a. This observa-
tion is, nonetheless, not surprising given that the classification was based
on a small number of participants contributing a large number of samples.
As expected, results tend to be less variable as we increase the number of
participants and decrease the number of samples per participant, as illus-
trated in Figure 6b, where results were based on 23 PD cases and 23 healthy
controls, each one contributing 44 samples (as opposed to 10 cases and 10
controls contributing 100 samples each).
Figure 6c reports results using all the “age matched” participants from
Figure 1, but a single “collapsed sample” per participant (namely, for each
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Fig 5. Train/test split where the data contributed by each participant is either included
in the training or in the test set. The schematic represents a data set composed of 4 PD
cases (participants 1 to 4), and 4 healthy controls (participants 5 to 8). Each participant has
data from n activity tasks, and the full feature data matrix is composed of 8n rows/samples
and p columns/features. The vector of case/control labels has 8n elements, with PD labels
shown in dark and healthy control labels shown in light color. The data of each participant
is randomly assigned to either the training or test set. In this example, the training set
received all the data (n samples) of participants 2, 3, 5, and 7, while the test set receives
the data of participants 1, 4, 6, and 8.
feature of each participant, we used the median of the feature values across
all longitudinal samples contributed by the participant as the collapsed fea-
ture value). Note that, in this case, the random train/test split described in
Figure 5 reduces to the standard train/test split for data sets containing a
single sample per participant. The figure reports results for both balanced
and un-balanced cases. For the tapping, voice, and walk/rest activities, the
un-balanced analysis was based, respectively, on 315 cases/109 controls, 277
cases/96 controls, and 170 cases/69 controls. For the balanced analyzes, we
randomly selected the number of PD case participants to match the respec-
tive number of healthy controls. The results show that while there is signal
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Fig 6. Panel a shows the performance comparison of the case/control (original labels)
versus random groups (block shuffled labels) classification, when the data contributed by
each participant is either included in the training or in the test set. Results are based in the
same data analyzed in Figure 4a (i.e., 10 cases, 10 controls with 100 samples from each),
but using the train/test split described in Figure 5. Panel b shows the same comparison,
but based in a larger number of participants (23 PD cases and 23 healthy controls), but a
smaller amount of longitudinal data (44 samples per participant). Note the smaller spread
of the boxplots in comparison to the results in panel a. Panel c shows the classification
performance based on larger number of participants, but using a single “collapsed sample”
per participant. The figure reports results for balanced and un-balanced cases. In all panels,
the grey boxplots represent the results for completely shuffled labels across all samples.
in the data to discriminate between cases and controls, the accuracy of the
classification is not particularly high.
Overall, our investigations suggest that, at least for clinical studies such
as the mPower that are run “in the wild”, a much larger number of partici-
pants and/or more sophisticated machine learning algorithms are necessary
in order to achieve state-of-the-art performance in the discrimination of PD
cases versus healthy controls using smartphone sensor data.
In the next section, we switch to our methodological contribution.
3. On the analysis of personalized medication response. We are
interested in determining whether a particular patient is responding to med-
ication, that is, we want to determine if the treatment X has an effect on
a outcome Y . Our focus is on the personalized level, as opposed to the
traditional focus of medicine, where the goal is to establish treatment effi-
cacy at a population level for a target cohort of patients[14, 15]. However,
since mPower is an observational study, the associations observed between
treatment and outcome measurements might be due to unmeasured con-
founders, and it is not possible to conclude with certainty that a difference
in performance between before/after medication tasks is actually due to the
10
medication. In particular, causal inferences at the personalized level are es-
pecially vulnerable to confounding effects that arise in a cyclic fashion over
the day (such as circadian rhythms and daily routine activities). For in-
stance, we observed in our data (Figure 7a) that some participants tended
to perform the “before medication” activity tasks earlier in the day than
the “after medication” tasks. For these participants, it is not possible to
conclude that an observed improvement in performance between tasks per-
formed before versus after medication are suggestive of a medication effect,
since the difference in performance might be due to daily cyclic confounders
(Figures 7b and c).
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Fig 7. Marginal associations between treatment (before/after medication status),
time-of-the-day and number of taps, for one study participant. Panel a shows that
the participant usually performs the before medication tapping tasks (red dots) earlier in
the day than the after medication tasks (blue dots). Panel b shows the participant also tends
to achieve better performance (larger number of taps) in tasks performed after medication.
Panel c, nonetheless, also shows that large number of taps tends to be associated with later
times. Hence, it is possible that the medication and/or circadian rhythms/daily routine
activities might be responsible for the difference in performance between the before and
after medication tapping tasks observed in this participant.
Fortunately, the time-of-the-day that the activity is performed is always
recorded by the smartphone, and we can use it as a surrogate variable for
circadian rhythms and daily routine confounders in our analyses. Hence,
the available data for the analyses corresponds to triplets, {X,T, Y } (where
T stands for the time of the day that the activity task was performed).
11
In the following we describe how we can use a subset of the conditional
independence relationships spanned by the {X,T, Y } variables in order the
determine whether a difference in performance might be due to a putative
treatment or putative “time-of-the-day” effect (or both).
3.1. Disentangling putative treatment effects from putative “time-of-the-
day” effects. Under the assumption that X, T , and Y are not influenced
by unmeasured confounders (in addition to other standard causal graphical
model assumptions mentioned at the end of this section), it is possible to
use a subset of the conditional independence relationships spanned by the
{X,T, Y } variables to determine if X has a causal effect on Y , or if T has a
causal effect on Y , or if both X and T have causal effects on Y , irrespective
of the causal relationship between X and T .
Explicitly, consider the putative causal models listed below.
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Models M1 and M4 are indistinguishable in terms of conditional indepen-
dence relationships. In the language of graphical models[16], M1 and M4 are
Markov equivalent1. Note that while M1 and M4 differ with respect to the
causal relation between X and T (where X → T in model 1, and X ← T
in model 4), both models represent a causal effect of the treatment on the
outcome (i.e., X → Y ). Similarly, M2 and M5 are Markov equivalent and
1A simple graphical criterion (Verma and Pearl 1990) for determining if two directed
and acyclic graphs (DAGs) are Marvov equivalent is to inspect if the DAGs have the
same skeleton and the same set of v-structures (where the skeleton of a DAG is obtained
by replacing the directed edges by undirect ones, and a v-structure is composed by two
converging arrows whose tails are not connected by an arrow). For instance, models M1
andM4 have the same skeleton, T X Y , and the same set of v-structures (namely,
no v-structures), and we say that models M1 and M4 belong to the same equivalence class.
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depict an effect of the time-of-the-day on the outcome, but no treatment ef-
fect, while M3 and M6 are Markov equivalent and represent the case where
both treatment and time-of-the-day effects influence the outcome. Models
M7, M8, and M9 represent, respectively, the causal DAGs for treatment,
time-of-the-day, and both effects in the case where X and T are not even
associated.
The subset of the conditional independence relations that can be used to
distinguish between the 6 equivalence classes of models, {M1,M4}, {M2,M5},
{M3,M6}, M7, M8, and M9, is given by,
(2)
Models T,X Y,X Y, T Y,X | T Y, T | X Putative effect
{M1,M4} T 6⊥⊥ X Y 6⊥⊥ X Y 6⊥⊥ T Y 6⊥⊥ X | T Y ⊥⊥ T | X treatment
{M2,M5} T 6⊥⊥ X Y 6⊥⊥ X Y 6⊥⊥ T Y ⊥⊥ X | T Y 6⊥⊥ T | X time-of-the-day
{M3,M6} T 6⊥⊥ X Y 6⊥⊥ X Y 6⊥⊥ T Y 6⊥⊥ X | T Y 6⊥⊥ T | X both
M7 T ⊥⊥ X Y 6⊥⊥ X Y ⊥⊥ T Y 6⊥⊥ X | T Y ⊥⊥ T | X treatment
M8 T ⊥⊥ X Y ⊥⊥ X Y 6⊥⊥ T Y ⊥⊥ X | T Y 6⊥⊥ T | X time-of-the-day
M9 T ⊥⊥ X Y 6⊥⊥ X Y 6⊥⊥ T Y 6⊥⊥ X | T Y 6⊥⊥ T | X both
where we adopt the notation ⊥⊥ and 6⊥⊥ to describe statistical independence
and dependence, respectively (and A ⊥⊥ B | C, to describe the statement
that A is independent of B conditional on C). Note that because the mea-
surement of the X and T variables precede the measurement of Y (so that
it is impossible for Y to have a causal influence on X or on T ) we don’t need
to consider any statistical dependencies that are conditional on Y .
By inspecting the results of the following 5 statistical tests,
(3)
H10 : T ⊥⊥ X vs H11 : T 6⊥⊥ X,
H20 : Y ⊥⊥ X vs H21 : Y 6⊥⊥ X,
H30 : Y ⊥⊥ T vs H31 : Y 6⊥⊥ T ,
H40 : Y ⊥⊥ X | T vs H41 : Y 6⊥⊥ X | T ,
H50 : Y ⊥⊥ T | X vs H51 : Y 6⊥⊥ T | X,
we are able to determine which among models {M1,M4}, {M2,M5}, {M3,M6},
M7, M8, and M9, are supported by the data. For instance, the rejection of
H10 , H
2
0 , H
3
0 , and H
4
0 together with the acceptance of H
5
0 , indicates that
the data supports M1 or M4, and that the association observed between X
and Y might be due to a treatment effect. Similarly, the rejection of the H30
and H50 together with the acceptance of H
1
0 , H
2
0 , and H
4
0 indicates that the
data supports M8. It is very important, nonetheless, to keep in mind that
the results of the conditional independence tests are only consistent with
the causal models in (1) under the assumption that there are no unmea-
sured confounders. Hence, the proposed approach can only detect putative
treatment and time-of-the-day effects. It is possible that, in reality, there
are no treatment or time-of-the-day effects and the associations between
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the {X,T, Y } measurements are actually due to unmeasured confounders.
For instance, the results of the conditional independence tests consistent
with {M1,M4} are also consistent with Ma in (4), where H represents an
unmeasured confounder (other than short term cyclic confounders, such as
circadian rhythms and daily routine schedules, for which the recorded time-
of-the-day works as a surrogate variable). Similarly, test results consistent
with models {M2,M5}, {M3,M6}, M7, M8, and M9, are also consistent with
Mb, Mc, Md, Me, and Mf , respectively.
(4) '& %$ ! "#T '& %$ ! "#T
}}||
||
||
Hoo

H //

'& %$ ! "#T Hoo
'& %$ ! "#X =={{{{{{ '& %$ ! "#Y '& %$ ! "#X '& %$ ! "#Y '& %$ ! "#X '& %$ ! "#Y
Ma H
``BBBBBB
??
Mb Mc H
``BBBBBB
??~~~~~~
'& %$ ! "#T '& %$ ! "#T Hoo

'& %$ ! "#T Hoo
'& %$ ! "#X '& %$ ! "#Y '& %$ ! "#X '& %$ ! "#Y '& %$ ! "#X '& %$ ! "#Y
Md H
``AAAAAA
??
Me Mf H
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??
In addition to the assumption of no unmeasured confounders, the above
approach also assumes the standard Markov properties for directed acyclic
graphs[16], and the faithfulness of the probability distribution to the graph
structure[17].
3.2. Accounting for serial association in the data. In practice, we are
interested in evaluating medication response at the personalized level and
we analyze the data from each participant separately. In this setting, the data
from each participant corresponds to a time series of treatment, time-of-the-
day, and outcome variables and it is natural to expect a serial correlation
structure in the data. Therefore, the causal graphs that we are actually
comparing are slightly more complicated than the graphs shown in (1). For
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instance, the model,
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represents a dynamic version of the causal graph M3 in (1), where we as-
sume that the serial correlation structure (that arises from the fact the the
data comes from the same participant) is represented by the autoregressive
structure of the residual error terms, t. (Note that the figure depicts a sim-
ple autoregressive serial association of order 1 only for illustrative purposes.
In practice, the residual correlation structure is unknown and can be much
more complicated.) The serially associated residual terms capture all factors
that are not accounted by the treatment or time-of-the-day but that still in-
fluence the outcome variable over time. For instance, the performance of
the participant (measured by the outcome variable) depends on the partici-
pant’s current physiological state. Hence, it is reasonable to expect that the
participant’s performance today was not very different from its performance
yesterday, and will not be very different from its performance tomorrow.
However, over a longer period of time, and as the disease progresses, it is
likely that the participant’s performance will change due to a more degraded
physiological state. Most importantly, observe that the same 5 conditional
independence tests can still be used to distinguish between the dynamic ver-
sions of models M1 to M9 (under the additional assumption that the time
series is stationary).
In our analyses, we adopt 3 distinct regression based approaches (which
account for the serial correlation structures for the residuals in different
ways). The first is a simple linear regression approach where we use standard
t-tests for carrying out the 5 conditional independence tests in (3) based on
4 linear regression model fits,
T = µ + βT,X X +  ,(6)
Y = µ + βY,X X +  ,
Y = µ + βY,T T +  ,
Y = µ + βY,X|T X + βY,T |X T +  ,
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where the conditional independence tests in (3) are performed by testing,
(7)
H10 : βT,X = 0 vs H
1
1 : βT,X 6= 0,
H20 : βY,X = 0 vs H
2
1 : βY,X 6= 0,
H30 : βY,T = 0 vs H
3
1 : βY,T 6= 0,
H40 : βY,X|T = 0 vs H41 : βY,X|T 6= 0,
H50 : βY,T |X = 0 vs H51 : βY,T |X 6= 0.
We employ the lm function of the R software[19] base distribution for these
analyses. Note that this approach naively assumes that the residuals of the
linear regression fits are uncorrelated. Whether the serial association struc-
ture of the residuals impact the t-tests depends on whether the study partic-
ipant performs the unmedicated and medicated activity tasks in a paired or
un-paired (and random) fashion over time. We describe this point in more
detail at the end of this section.
The second approach is based on regression with ARIMA errors model-
ing, where we basically fit the same 4 regression models in equations (6), but
where the serial association of the residual errors are modeled according to
an ARIMA (autoregressive integrated moving average) [20] process. Because
the residual correlation structure is unknown, we employ the auto.arima
function of the forecast R package[21] in order to first select the autore-
gressive, moving average, and differencing orders of the models that are
used to test the hypothesis in (7). One caveat of this approach is that the
ARIMA modeling assumes the data is equally spaced, what is not true in
our application.
The third approach is based on regression modeling with heteroscedas-
ticity, and autocorrelation consistent (HAC) covariance matrix estimation.
Non-parametric and kernel based HAC estimators are able to account for
heteroscedasticity, and autocorrelation of unknown form, and can be used to
construct statistical tests that are robust to violations of homoscedasticity
and independent error assumptions. Here, we adopted the Newey-West HAC
estimator[22], using Bartlett kernel, and the automatic bandwidth selection
procedure described in reference[23], and implemented in the sandwich R
package[24], in order to construct robust t-tests for the same 4 regression
models in equations (6). While HAC estimation still assumes the data is
equally spaced, it has been shown that application of the Newey-West esti-
mator to time series with missing data (and, hence, unequally spaced) still
generates asymptotically consistent estimates of the covariance matrix, as
well as, reasonable performance in finite sample simulation studies[25, 26].
3.3. Union-intersection tests for putative treatment effects and putative
“time-of-the-day” effects. In the previous section we described how to test
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for putative treatment and time-of-the-day effects for a single feature (out-
come variable). In practice, however, we have multiple features and need
to combine them into a single decision procedure. Here, we describe union-
intersection (UI) tests for combining the feature specific tests into a single
testing procedure.
Explicitly, suppose we have p features indexed from k = 1, . . . , p. The UI-
test for a putative treatment effect is constructed by combining the feature
specific tests,
(8) H0k : βY,X|T = 0 vs H1k : βY,X|T 6= 0 ,
or,
(9) H0k : βY,X = 0 vs H1k : βY,X 6= 0 ,
into a single test,
(10) H0 : ∩pk=1H0k vs H1 : ∪pk=1H1k ,
where we use the time-of-the-day adjusted test in (8) when the data as-
sociated with feature k, {X,T, Yk}, is consistent with the models M2, M3,
M5, M6, M8, and M9 in (1), and the un-adjusted test in (9) otherwise. Note
that because we are interested in detecting the (putative) direct effect of the
treatment on the outcome, the choice to adjust or not for the time-of-the-
day variable is tailored to the DAG structure (since the direct effect of X
on Y , implied by a DAG, corresponds to the effect of X on Y conditional on
all parents of Y , other than X). (Observe, as well, that, at times, the condi-
tional independence patterns in the data might not be consistent with any of
the 9 models in (1), due to random noise or confounder induced biases, such
as, M bias[29]. In these situations we don’t adjust for the time-of-the-day as
well.)
Similarly, the UI-test for a putative time-of-the-day effect is built by com-
bining the feature specific tests,
(11) H0k : βY,T |X = 0 vs H1k : βY,T |X 6= 0 ,
or,
(12) H0k : βY,T = 0 vs H1k : βY,T 6= 0 ,
into the single test where we use the treatment adjusted test in (11) when
the data is consistent with models M1, M3, M4, M6, M7, and M9, and the
un-adjusted test in (12) otherwise.
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Described in words, the UI-test for putative treatment (time-of-the-day)
effect compares the null hypothesis of no putative treatment (time-of-the-
day) effect for all features, against the alternative that there is a putative
treatment (time-of-the-day) effect for at least one of the features. Under
this test, we reject the null if the p-value of at least one of the feature-
specific tests is small. Hence, the p-value for the UI-test corresponds to
the smallest p-value (across all p features) after multiple testing correction.
Note, nonetheless, that because the covariate adjustment in the UI-tests are
tailored to inferred DAG structures, the multiple testing correction needs
to account for this as well. Hence, the correction is based on 4 p + 1 tests,
since for each one of the p features the determination of whether the data
supports any of the models in (1) is based on the 5 tests in equation (7),
but where the first one (H10 : βT,X = 0 vs H
1
1 : βT,X 6= 0) is the same across
all p features.
Finally, note that the UI-tests can be constructed using the output of
any of the 3 linear regression approaches (standard, ARIMA errors, and
Newey-West) described in the previous section.
3.4. Data processing. For each participant, the data from each extracted
feature was separately de-trended with a lowess smoother (so that our fea-
ture data, actually corresponds to the residuals of a lowess fit to the data
point collection index). The data was also transformed to an approximately
normal distribution using a rank-quantile transformation,
(13) Φ−1
(
ri − 0.5
n
)
,
where Φ() represents the cumulative density function of the standard normal
random variable, ri represents the rank of the outcome value, yi, and n
represents the number of outcome data points.
3.5. On the validity of t-tests in the presence of serial correlation. Whether
residual autocorrelation impacts the type I error rates of t-tests depends on
whether a participant performs the activity tasks in a paired or unpaired
(and close to random) fashion. For instance, if a participant tends to per-
form both the unmedicated and medicated activity tasks every day (so that
the data is paired by day), the residual autocorrelation can have a strong
impact on the t-test p-values. In the context of paired time series, it has
been shown that for positive serial correlation the F-test distribution (and,
hence, the equivalent t-test in our binary treatment case) has a thicker up-
per tail than when the serial correlation is zero, while for negative serial
correlation the upper tail is thinner[28]. As a consequence, the t-tests are
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conservative in the presence of positive autocorrelation (i.e., the p-values
tend to be larger than they should), and anti-conservative in the presence
of negative autocorrelation (i.e., the p-values tend to be smaller than they
should). On the other hand, if a participant tends to perform the tasks in
an unpaired fashion (i.e., the before and an after medication tasks are not
performed on the same day), with no particular structure about the order of
the before/after tasks, then the presence of residual autocorrelation does not
impact the p-value of a t-test, since the group labels (before/after medica-
tion) are exchangeable under the null hypothesis of no putative medication
effect. (For further details see reference[3], where it was implicitly assumed
that most participants performed the before/after medication tasks in an
unpaired and mostly random fashion).
3.6. Results. One of the goals of the mPower study is to assess if data
collected by smartphones can be used to evaluate the efficacy of a new drug
or intervention. To this end, we investigated whether participants showed
a response to dopaminergic medication by comparing their performance in
activity tasks performed before the participant has taken medication versus
after medication. The longitudinal data of each participant was analyzed
separately (as we are interested in determining if a given participant is re-
sponding or not to medication, as opposed to determining if dopaminergic
drugs have an effect on the study cohort). For each activity task, we re-
stricted the analyses to participants that performed at least 15 tasks before
taking medication and 15 tasks after medication (106, 99, 58, and 57, par-
ticipants for the tapping, voice, walk, and rest tasks, respectively).
Our analyses suggests that approximately 37%, 42%, 33%, and 16% of the
participants showed a putative medication response (for at least one of the
extracted features) in the tapping, voice, walk, and rest tasks, respectively,
according to the union-intersection test for putative medication response
based on naive linear regression models with Benjamini-Hochberg multiple
testing correction at 5% FDR (8a).
Figure 8a shows that the participant’s responses are highly individualized,
with different participants showing strong putative medication effects in
different activity tasks, and often times showing a response in one activity
but not in another. We point out, nonetheless, that this observation is not
surprising since Parkinson disease shows a wide spectrum of symptoms, and
different patients show different sets of symptoms.
Figure 8b suggests that approximately 40%, 69%, 47%, and 19% of the
participants showed a potential time-of-the-day response in the tapping,
voice, walk, and rest tasks, respectively (according to the analogous union-
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Fig 8. Personalized response to medication (standard linear regression). Panels
a and b show the adjusted p-values (in -log10 scale) for the union-intersection tests for pu-
tative medication effects and putative time-of-the-day effects, respectively. The black line
corresponds to a p-value threshold of 0.05. Panel c shows a matrix with the results of our
medication vs time-of-the-day disentangling approach for all features (rows) and partici-
pants (columns). Green and red cells indicate, respectively, putative treatment and putative
time-of-the-day effects, while black cells indicate both effects. White cells represent non-
significant effects or missing data. The order of the participants in the x-axis of panels a, b,
and c is the same, with the participants sorted according to the average putative treatment
effect across the 4 activity tasks. Panels d and e show scatter plots of the disease onset year
by adjusted p-values for putative medication and putative time-of-the-day effects, respec-
tively. The blue dots represent the responders (i.e., participants that showed a significant
putative medication effect in panel d, and putative time-of-the-day effect in panel e). The
blue and red regression lines were fitted to the blue and red points, respectively, while the
black regression line was computed using all points. The p-values for testing for zero slope
of the regression lines are provided in the top right corner of the panels. Results were based
on the data pooled across the 4 activity tasks. Panels f and g show analogous plots for the
association with the year that the participant started taking medication.
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intersection test for putative time-of-the-day effects, described above). Over-
all, we observed a larger proportion of putative time-of-the-day effects in all
activities, but especially so for the voice task.
Figure 8c presents the results of our disentangling approach for each par-
ticipant/feature combination. Green, red, and black cells indicate, respec-
tively, putative treatment, putative time-of-the-day, and both putative treat-
ment and time-of-the-day effects, while white cells represents non-significant
effects or missing data (some participants didn’t provide any data for some
of the activity tasks). It is interesting to note that except for the voice fea-
tures, where putative time-of-the-day effects are very common and some
participants tended to show a somewhat balanced number of green and red
cells, most participants tended to be dominated by either green or red cells.
In particular, the participants in the left side of the matrix tended to show
a higher proportion of putative medication effects (green cells). The consis-
tent detection of putative medication response across several features for the
same participant provides additional evidence that the effect might be real.
(The less consistent results and larger proportion of time-of-the-day effects
in the voice features, might be due to background noise.)
Figure 8d shows a statistically significant association (p<0.0005) between
the p-values (in -log10 scale) of the union-intersection test for putative treat-
ment effects and the disease onset year of the study participants, showing
that participants living with Parkinson’s disease for several years tend to
show the strongest differences in performance before and after taking med-
ication. This finding agrees with what is observed in clinic, where it gets
more difficult to control Parkinson’s disease symptoms with dopaminergic
medication as time goes by. As a sanity check, we also inspected the associa-
tion between putative time-of-the-day effects and disease onset year (Figure
8e). As expected, no association was found (p<0.304). Figures 2f and 2g
show analogous results for the association with the year that the participant
started taking medication. These results provide further evidence that the
observed putative medication effects might be real.
All results presented above were based on naive linear regression model
fits, where we ignored the time series structure of the data. However, as
pointed out above, whether residual autocorrelation impacts the type I error
rates of t-tests depends on whether a participant performs the activity tasks
in a paired or unpaired (and close to random) fashion.
In the mPower study, it is the participant who decides whether he/she will
perform the activity before or after taking medication every time the par-
ticipant performs a task. Inspection of the mPower’s before/after label data
shows a wide range of patterns ranging from completely unpaired (i.e., never
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performing a before and an after medication task on the same day) to al-
most perfectly paired (Figure 9a). Because some of the participants with the
most significant p-values in the standard linear regression approach tended
to perform the activity tasks in a more paired fashion (Figure 9b), it is im-
portant to investigate the residual autocorrelation of the linear regression
models in order to assess if the p-values have been artificially inflated by
negative autocorrelations.
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Fig 9. Before/after medication patterns. Panel a shows the distribution of the “parity
score” of all participants, across all activity tasks. The parity score was defined as the
proportion of days where the participant performed an activity tasks before and after taking
medication on the same day. Panel b shows a scatter plot of the parity score versus the
putative treatment effect p-values (in -log10 scale) from the linear regression models used
in the analysis presented in Figure 8.
Inspection of the residual autocorrelation structure shows, nonetheless,
that most of the statistically significant autocorrelations are positive (Figure
10). This observation suggests that the results from the naive linear regres-
sion analyses are likely conservative, and that more sophisticated analyses
accounting for autocorrelation might be better powered to detect putative
medication (and putative time-of-the-day) effects.
Re-analysis of the data using regression with ARIMA errors and regression
with Newey-West HAC covariance estimation confirms that modeling of the
autocorrelation structure improves the power to detect putative treatment
effects (Table 1) and putative time-of-the-day effects (Table 2).
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Fig 10. Residual autocorrelation of the linear regression model fits. The heatmap
in the left shows the autocorrelation (lag equal to 1) of the residuals of the linear regression
model fits for each feature and participant combination. Red and green represents, respec-
tively, negative and positive autocorrelation. White represents missing data (as some par-
ticipants did not provide data for all activity tasks). The heatmap in the right shows only
the autocorrelation values that were statistically different from zero according to multiple
testing corrected Ljung-Box tests (based on lag equal to 1) at a significance threshold of
0.05. (The autocorrelation values that were not statistically significant are shown in white
together with the missing data.) Only about 3.7% of the statistically significant autocorre-
lations were negative.
Figures 11 and 12 present the same comparisons reported on Figure 8,
but based on the regression with ARIMA errors and on the regression with
Newey-West HAC covariance estimation approaches, respectively. Apart
from the higher power to detect statistically significant putative effects, the
figures illustrate that the results from all 3 analyses were largely consistent.
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regr. approach tapping voice walk rest any activity
standard (lm) 37% 42% 33% 16% 60%
ARIMA errors 42% 46% 46% 21% 69%
Newey-West 45% 37% 42% 24% 67%
Table 1
Proportion of participants showing statistically significant putative treatment
effects, across the 3 distinct analysis approaches. The last column shows the
proportion of participants that showed a statistically significant putative medication effect
in at least one of the four activity tasks.
regr. approach tapping voice walk rest any activity
standard (lm) 40% 69% 47% 19% 78%
ARIMA errors 45% 76% 53% 22% 86%
Newey-West 57% 66% 68% 28% 83%
Table 2
Proportion of participants showing statistically significant putative
time-of-the-day effects, across the 3 distinct analysis approaches. The last
column shows the proportion of participants that showed a statistically significant
putative time-of-the-day effect in at least one of the four activity tasks.
4. Discussion. This work provides two main contributions to the anal-
ysis of longitudinal data collected by smartphones in mobile health appli-
cations. In our first contribution, we proposed a novel statistical approach
to disentangle putative treatment effects from putative “time-of-the-day”
effects in observational studies.
The key insight that makes the approach practical is the realization that in
our mobile health application, the measurement of the treatment and time-
of-the-day variables precedes the measurement of the outcome variable, so
that any causal models where the outcome plays the role of a cause of the
treatment or time-of-the-day variables are automatically disregarded, and
it is possible to use a few conditional independence relationships to distin-
guish between treatment and time-of-the-day (or both) effects, irrespective
of the causal relation between treatment and time-of-the-day variables. The
ability to tell apart treatment and time-of-the-day effects is very important
in practice, since any causal inferences about personalized treatment effects
are especially vulnerable to daily cyclic confounding factors, such as circa-
dian rhythms and daily routine activities. Application of the method to the
mPower data suggests that some participants are responding to the medica-
tion, while others seem to be responding mostly to time-of-the-day. While
the proposed method was motivated by the mPower study, the approach
is quite general and we anticipate that the mobile health community might
find this tool useful for other applications assessing personalized treatments.
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Fig 11. Personalized response to medication based on the regression with ARIMA
errors approach. Panels a and b show the adjusted p-values for the union-intersection
tests for putative medication effects and putative time-of-the-day effects, respectively. The
black line corresponds to a p-value threshold of 0.05. Panel c shows a matrix with the
results of our medication vs time-of-the-day disentangling approach for all features (rows)
and participants (columns). Green and red cells indicate, respectively, putative treatment
and putative time-of-the-day effects, while black cells indicate both effects. White cells
represent non-significant effects or missing data. The order of the participants in the x-
axis of panels a, b, and c is the same, with the participants sorted according to the average
putative treatment effect across the 4 activity tasks. Panels d and e show scatter plots of
the disease onset year by adjusted p-values for putative medication and putative time-of-
the-day effects, respectively. The blue dots represent the responders (i.e., participants that
showed a significant putative medication effect in panel d, and putative time-of-the-day
effect in panel e). The blue and red regression lines were fitted to the blue and red points,
respectively, while the black regression line was computed using all points. The p-values
for testing for zero slope of the regression lines are provided in the top right corner of the
panels. Results were based on the data pooled across the 4 activity tasks. Panels f and g
show analogous plots for the association with the year that the participant started taking
medication.
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Fig 12. Personalized response to medication based on the regression with Newey-
West HAC covariance estimation approach. Panels a and b show the adjusted p-
values for the union-intersection tests for putative medication effects and putative time-of-
the-day effects, respectively. Panel c shows a matrix with the results of our medication vs
time-of-the-day disentangling approach for all features (rows) and participants (columns).
Green and red cells indicate, respectively, putative treatment and putative time-of-the-
day effects, while black cells indicate both effects. White cells represent non-significant
effects or missing data. The order of the participants in the x-axis of panels a, b, and c
is the same, with the participants sorted according to the average putative treatment effect
across the 4 activity tasks. Panels d and e show scatter plots of the disease onset year by
adjusted p-values for putative medication and putative time-of-the-day effects, respectively.
The blue dots represent the responders (i.e., participants that showed a significant putative
medication effect in panel d, and putative time-of-the-day effect in panel e). The blue and
red regression lines were fitted to the blue and red points, respectively, while the black
regression line was computed using all points. The p-values for testing for zero slope of
the regression lines are provided in the top right corner of the panels. Results were based
on the data pooled across the 4 activity tasks. Panels f and g show analogous plots for the
association with the year that the participant started taking medication.
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Our second contribution was to show that smartphone data collected from
of a given study participant can represent a “digital signature”, or a “digital
fingerprint”, of the participant. As a consequence, one needs to be careful
when designing the train/test split of the data used to train a case/control
classifier. Explicitly, if data from each participant is included in both the
training and test set, then the classifier performance can be artificially im-
proved because it is easy to discriminate one participant from another. In
order to avoid this artifact, one should instead adopt a train/test split where
the data contributed by each participant is either included in the training or
in the test set. Finally, we point out that while the present work has char-
acterized the digital fingerprint issue in a Parkinson’s disease application,
this phenomenon might potentially show up in other applications employing
data collected from highly sensitive sensors, and might represent a common
artifact in mobile health studies in general.
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